Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegzilarginase - Spyre Therapeutics

Next Previous
Drug Profile

Pegzilarginase - Spyre Therapeutics

Alternative Names: AEB-1102; AERase; Co-ArgI-PEG - Spyre Therapeutics; Co-ArgI-PEG modified human arginase I - Spyre Therapeutics; Loargys; Optimised human arginase I - Spyre Therapeutics; PEG-arginase - Spyre Therapeutics; Pegarginase - Spyre Therapeutics

Latest Information Update: 26 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aeglea Biotherapeutics
  • Developer Merck AG; Spyre Therapeutics
  • Class Antineoplastics; Enzymes; Immunotherapies; Polyethylene glycols; Recombinant proteins; Ureohydrolases
  • Mechanism of Action Arginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperargininaemia
  • New Molecular Entity No

Highest Development Phases

  • Registered Hyperargininaemia
  • Phase I/II Small cell lung cancer
  • No development reported Non-small cell lung cancer; Solid tumours
  • Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 21 Dec 2023 Preregistration for Hyperargininaemia (In adolescents, In children, In the elderly, In adults) in United Kingdom (IV) Prior to December 2023
  • 21 Dec 2023 Registered for Hyperargininaemia (In adolescents, In children, In the elderly, In adults) in United Kingdom (IV)
  • 21 Dec 2023 Pegzilarginase - Aeglea BioTherapeutics receives Orphan Drug status for Hyperargininaemia (In adolescents, In adults, In children, In the elderly) in United Kingdom
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top